New FDA Guidelines Released For Biosimilars

The Food and Drug Administration released a guidelines draft for “biosimilars,” less expensive, “generic” versions which are closer to becoming available on pharmacy shelves

Biosimilars will be substitutes for biologic products already used to treat a variety of conditions, including rheumatoid arthritis, cancer and diabetes.

More information on the new regulations for biosimilars can be read at this link.

This entry was posted on March 21, 2012, in News. Bookmark the permalink.